Effect of silencing the T‑Box transcription factor TBX2 in prostate cancer PC3 and LNCaP cells

Du,Wen‑Liang; Fang,Qian; Chen,Yue; Teng,Jing‑Wei; Xiao,Yong‑Shuang; Xie,Ping; Jin,Bo; Wang,Jun‑Qi

doi:10.3892/mmr.2017.7361

Effect of silencing the T‑Box transcription factor TBX2 in prostate cancer PC3 and LNCaP cells

Authors:
- Wen‑Liang Du
- Qian Fang
- Yue Chen
- Jing‑Wei Teng
- Yong‑Shuang Xiao
- Ping Xie
- Bo Jin
- Jun‑Qi Wang
View Affiliations

Affiliations: Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China
Published online on: August 24, 2017 https://doi.org/10.3892/mmr.2017.7361
Pages: 6050-6058
Copyright: © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

T‑Box (TBX)‑2 is a member of the T‑box gene family, which is aberrantly expressed in numerous types of malignant tumors, and has previously been demonstrated to be conducive to tumor progression by acting as a transcription factor. However, specific information regarding the expression and function of TBX2 in prostate cancer cells remains to be elucidated. The present study demonstrated that silencing of TBX2 by TBX2 small interfering RNA inhibited cell proliferation and promoted cell senescence. It was demonstrated that knockdown of TBX2 inhibited cell metastatic abilities by upregulating E‑cadherin and downregulating N‑cadherin, Vimentin and fibronectin. In addition, the expression of TBX2 in prostate cancer tissues and tumor adjacent tissues was detected by immunohistochemistry. The results indicated that the expression rates of TBX2 were significantly increased in the cancerous tissues, compared with the healthy tumor adjacent tissue, and TBX2 increased staining was associated with the clinical stage and pathological grade. The findings of the present study therefore suggest that TBX2 expression is markedly increased in prostate cancer and TBX2 may act as a potential beneficial therapeutic target for the future treatment of prostate cancer.

View Figures

View References

1	D'Costa ZC, Higgins C, Ong CW, Irwin GW, Boyle D, McArt DG, McCloskey K, Buckley NE, Crawford NT, Thiagarajan L, et al: TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: A novel cancer-selective target pathway with therapeutic opportunities. Oncotarget. 5:1609–1620. 2014. View Article : Google Scholar : PubMed/NCBI
2	Wang B, Lindley LE, Fernandez-Vega V, Rieger ME, Sims AH and Briegel KJ: The T box transcription factor TBX2 promotes epithelial-mesenchymal transition and invasion of normal and malignant breast epithelial cells. PLoS One. 7:e413552012. View Article : Google Scholar : PubMed/NCBI
3	Han Y, Tu WW, Wen YG, Yan DW, Qiu GQ, Peng ZH and Zhou CZ: Increased expression of TBX2 is a novel independent prognostic biomarker of a worse outcome in colorectal cancer patients after curative surgery and a potential therapeutic target. Med Oncol. 30:6882013. View Article : Google Scholar : PubMed/NCBI
4	Vance KW, Carreira S, Brosch G and Goding CR: Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res. 65:2260–2268. 2005. View Article : Google Scholar : PubMed/NCBI
5	Liu WK, Jiang XY and Zhang ZX: Expression of PSCA, PIWIL1, and TBX2 in endometrial adenocarcinoma. Onkologie. 33:241–245. 2010. View Article : Google Scholar : PubMed/NCBI
6	Baldwin RL, Tran H and Karlan BY: Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling. Cancer Res. 63:1413–1419. 2003.PubMed/NCBI
7	Li J, Ballim D, Rodriguez M, Cui R, Goding CR, Teng H and Prince S: The anti-proliferative function of the TGF-β1 signaling pathway involves the repression of the oncogenic TBX2 by its homologue TBX3. J Biol Chem. 289:35633–35643. 2014. View Article : Google Scholar : PubMed/NCBI
8	Jerome-Majewska LA, Jenkins GP, Ernstoff E, Zindy F, Sherr CJ and Papaioannou VE: Tbx3, the ulnar-mammary syndrome gene, and Tbx2 interact in mammary gland development through a p19Arf/p53-independent pathway. Dev Dyn. 234:922–933. 2005. View Article : Google Scholar : PubMed/NCBI
9	Redmond KL, Crawford NT, Farmer H, D'Costa ZC, O'Brien GJ, Buckley NE, Kennedy RD, Johnston PG, Harkin DP and Mullan PB: T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells. Oncogene. 29:3252–3262. 2010. View Article : Google Scholar : PubMed/NCBI
10	Rowley M, Grothey E and Couch FJ: The role of Tbx2 and Tbx3 in mammary development and tumorigenesis. J Mammary Gland Biol Neoplasia. 9:109–118. 2004. View Article : Google Scholar : PubMed/NCBI
11	Vance KW, Shaw HM, Rodriguez M, Ott S and Goding CR: The retinoblastoma protein modulates Tbx2 functional specificity. Mol Biol Cell. 21:2770–2779. 2010. View Article : Google Scholar : PubMed/NCBI
12	Balogová L, Maslaňáková M, Dzurová L, Miškovský P and Stroffeková K: Bcl-2 proapoptotic proteins distribution in U-87 MG glioma cells before and after hypericin photodynamic action. Gen Physiol Biophys. 32:179–187. 2013. View Article : Google Scholar : PubMed/NCBI
13	Hojabrpour P, Waissbluth I, Ghaffari M, Cox ME and Duronio V: CaMKII-γ mediates phosphorylation of BAD at Ser170 to regulate cytokine-dependent survival and proliferation. Biochem J. 442:139–149. 2012. View Article : Google Scholar : PubMed/NCBI
14	Chao DT and Korsmeyer SJ: BCL-2 family: Regulators of cell death. Annu Rev Immunol. 16:395–419. 1998. View Article : Google Scholar : PubMed/NCBI
15	Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 26:1324–1337. 2007. View Article : Google Scholar : PubMed/NCBI
16	Courtney KD, Corcoran RB and Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol. 28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
17	Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
18	Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
19	Bertram J, Peacock JW, Tan C, Mui AL, Chung SW, Gleave ME, Dedhar S, Cox ME and Ong CJ: Inhibition of the phosphatidylinositol 3′-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells. Cancer Res. 66:4781–4788. 2006. View Article : Google Scholar : PubMed/NCBI
20	Tan XL, Guo L and Wang GH: Polyporus umbellatus inhibited tumor cell proliferation and promoted tumor cell apoptosis by downregulating AKT in breast cancer. Biomed Pharmacother. 83:526–535. 2016. View Article : Google Scholar : PubMed/NCBI
21	Radisky DC and LaBarge MA: Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell. 2:511–512. 2008. View Article : Google Scholar : PubMed/NCBI
22	Bonavida B and Baritaki S: Inhibition of Epithelial-to-Mesen chymal Transition (EMT) in cancer by nitric oxide: Pivotal roles of nitrosylation of NF-κB, YY1 and Snail. For Immunopathol Dis Therap. 3:125–133. 2012. View Article : Google Scholar : PubMed/NCBI
23	Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 117:927–939. 2004. View Article : Google Scholar : PubMed/NCBI
24	Kang Y and Massagué J: Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
25	Ferrara N: VEGF as a therapeutic target in cancer. Oncology 69 Suppl. 3:11–16. 2005. View Article : Google Scholar
26	Kowanetz M and Ferrara N: Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin Cancer Res. 12:5018–5022. 2006. View Article : Google Scholar : PubMed/NCBI